Seer (SEER) AI Stock Analysis

• Market Cap: $122.17M
• Dividend Yield: N/A
• Average Volume (3M): 113.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 13.77%
• EPS Growth: -4.76%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.32
• Shares Outstanding: 51,759,773
• 10 Day Avg. Volume: 70,395
• 30 Day Avg. Volume: 113,152
• PEG Ratio: -0.56
• Price to Book (P/B): 0.44
• Price to Sales (P/S): 10.33
• P/FCF Ratio: -2.90
• Enterprise Value/Market Cap: -0.50
• Enterprise Value/Revenue: -3.72
• Enterprise Value/Gross Profit: -9.13
• Enterprise Value/Ebitda: 0.85
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $2.00 ▲(1.52% Upside)

Seer's overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability challenges. Technical analysis suggests a potential upward trend, but valuation concerns due to ongoing losses weigh heavily. The earnings call provided mixed signals, with strong demand offset by minimal growth and external challenges.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Seer's products, enhancing its market position and supporting long-term business expansion.

Innovative Product Offering

The Proteograph platform's wide application in critical research areas underscores Seer's innovative edge and potential for sustained relevance in proteomics.

Strategic Partnerships

Strategic partnerships, like with Thermo Fisher, enhance Seer's market reach and collaborative potential, fostering long-term growth opportunities.

Negative Factors

Profitability Challenges

Substantial profitability challenges highlight operational inefficiencies, which could impede Seer's ability to achieve sustainable financial health.

Cash Flow Issues

Declining cash flow growth suggests financial strain, potentially limiting Seer's capacity to invest in growth initiatives and manage operational costs.

Government Funding Uncertainty

Dependence on government funding introduces uncertainty, affecting Seer's revenue predictability and strategic planning in the long term.

Seer Business Overview & Revenue Model

Company Description

Seer (SEER) is a biotechnology company focused on revolutionizing the field of proteomics through its innovative technologies. The company operates in the life sciences sector, specializing in the development of tools and services for protein analysis, which are critical for drug discovery and development. Seer's core products include its proprietary proteomic platforms that enable researchers to gain insights into protein function and interactions at an unprecedented scale and resolution.

How the Company Makes Money

Seer generates revenue primarily through the sale of its proteomic analysis platforms and related consumables to research institutions and pharmaceutical companies. Additionally, the company may earn revenue through service contracts where it conducts custom proteomic analyses for clients. Key partnerships with academic institutions and collaborations with pharmaceutical companies enhance its market presence and provide opportunities for joint research projects, which can also contribute to its earnings. Furthermore, grants and funding from governmental and private entities aimed at advancing proteomic research can serve as additional revenue sources.

Seer Financial Statement Overview

Summary

Seer shows strong revenue growth but faces significant profitability and cash flow challenges. The low leverage is positive, but negative returns on equity and cash flow issues highlight the need for operational improvements.

Income Statement

Seer's income statement shows a significant revenue growth of 54.8% in the TTM period, indicating strong top-line expansion. However, the company is facing substantial profitability challenges with a negative net profit margin of -510.57% and negative EBIT and EBITDA margins. These figures highlight ongoing operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet reflects a conservative financial structure with a low debt-to-equity ratio of 0.086, suggesting limited leverage and financial risk. However, the return on equity is negative at -25.93%, indicating that the company is not generating positive returns on shareholders' equity, which is a concern for investors.

Cash Flow

Seer's cash flow statement shows a decline in free cash flow growth by -15.53% in the TTM period, which is concerning. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. However, the free cash flow to net income ratio is slightly positive at 1.06, suggesting some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.33M	13.95M	15.18M	14.69M	6.39M	656.00K
Gross Profit	6.65M	6.83M	1.45M	384.00K	-374.00K	-950.00K
EBITDA	-71.41M	-93.92M	-80.70M	-87.06M	-67.61M	-31.17M
Net Income	-79.35M	-86.60M	-86.28M	-92.97M	-71.17M	-32.77M
Balance Sheet
Total Assets	308.61M	366.60M	436.27M	487.93M	539.14M	442.32M
Cash, Cash Equivalents and Short-Term Investments	199.24M	236.41M	316.22M	421.24M	400.07M	431.86M
Total Debt	24.25M	25.96M	28.26M	29.87M	23.32M	0.00
Total Liabilities	36.79M	39.03M	39.37M	40.94M	36.22M	10.71M
Stockholders Equity	271.81M	327.57M	396.90M	446.99M	502.92M	431.61M
Cash Flow
Free Cash Flow	-46.07M	-49.69M	-66.37M	-71.05M	-53.27M	-25.36M
Operating Cash Flow	-45.10M	-46.11M	-59.06M	-60.78M	-46.35M	-20.83M
Investing Cash Flow	64.42M	65.86M	37.90M	-122.72M	-170.88M	-34.56M
Financing Cash Flow	-11.97M	-11.49M	452.00K	3.89M	116.63M	371.49M

Seer Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEER, the sentiment is Negative. The current price of 1.97 is below the 20-day moving average (MA) of 2.12, below the 50-day MA of 2.17, and below the 200-day MA of 2.08, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 35.87 is Neutral, neither overbought nor oversold. The STOCH value of 30.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SEER.

Seer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	54 Neutral	$122.17M	-1.58	-25.74%	―	13.77%	-4.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IKT	46 Neutral	$118.48M	-1.46	-131.71%	―	-100.00%	79.01%
SRZN	43 Neutral	$107.90M	-0.90	―	―	-63.96%	-28.50%
CGTX	41 Neutral	$138.51M	-2.39	-109.73%	―	―	50.39%
TCRX	41 Neutral	$54.64M	-0.86	-76.44%	―	-10.03%	11.06%
TIL	34 Underperform	$89.12M	―	-50.60%	―	―	1.40%

Seer Corporate Events

Seer, Inc. Reports Modest Revenue Growth in Q3 2025

Seer, Inc., a leader in deep, unbiased proteomics, offers advanced solutions for biological insights through its Proteograph Product Suite, catering to the research sector.

Seer Appoints Isaac Ro to Board of Directors

On September 2, 2025, Seer, Inc. announced the appointment of Isaac Ro to its Board of Directors, where he will also serve as a member of the Audit Committee. Mr. Ro’s extensive experience in financial leadership and the healthcare sector is expected to help Seer achieve transformative growth and enhance its platform’s impact. His appointment resolves any potential non-compliance with Nasdaq Listing Rules, and he will receive compensation in line with Seer’s outside director compensation policy.

The most recent analyst rating on (SEER) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Seer stock, see the SEER Stock Forecast page.

Seer, Inc. Earnings Call: Optimism Amid Challenges

Seer, Inc. Earnings Call: A Cautiously Optimistic Outlook

Seer, Inc. Reports Strong Q2 2025 Growth and Innovations

Seer, Inc. is a leading life sciences company specializing in proteomics, offering innovative solutions that provide unprecedented insights with its Proteograph Product Suite. The company operates within the biotechnology sector and is known for its disruptive approach to proteomics research.